Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Royalty obligation (Details)

v3.19.3.a.u2
Royalty obligation (Details)
$ in Thousands
12 Months Ended
Mar. 08, 2012
officer
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Disclosure of Commitments [Line Items]      
Royalty obligation (note 12) | $   $ 7,200 $ 0
Voclosporin      
Disclosure of Commitments [Line Items]      
Licensee royalty fee 2.00% 2.00%  
Royalty fee if product is sold by the Company 0.30%    
Royalty fee if the Company sells all of product to third party through transfer 0.30%    
Number of executives eligible to receive royalties | officer 2    
Percent of royalty revenue if the of product is sold by licensee 0.1675%    
Percent of royalty revenue if the of product is transferred to sold by Company 0.025%    
Percent of royalty revenue if the of product is transferred to third party 0.025%